menu search

INSM / Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation— —Researchers to Present Subgroup Analysis from Phase 2 WILLOW Study Evaluating Brensocatib Treatment Outcomes by Disease Severity in Patients with Bronchiectasis— BRIDGEWATER, N.J. , March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE ® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C. Read More
Posted: Mar 24 2023, 16:22
Author Name: PRNewsWire
Views: 102081

INSM News  

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
October 26, 2023

Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 more_horizontal

Why Shares of Insmed Are Soaring This Week

By The Motley Fool
September 8, 2023

Why Shares of Insmed Are Soaring This Week

Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter. more_horizontal

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

By Zacks Investment Research
September 6, 2023

Insmed (INSM) Up on Positive Data From MAC Lung Disease Study

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC. more_horizontal

Insmed stock climbs on positive study results; hits 52-week high

By Proactive Investors
September 5, 2023

Insmed stock climbs on positive study results; hits 52-week high

Insmed Incorporated (NASDAQ:INSM) shares jumped 18% to $26.62 after the biopharmaceutical company revealed that nearly 44% of patients with nontube more_horizontal

Why Insmed Stock Is Soaring Today

By The Motley Fool
September 5, 2023

Why Insmed Stock Is Soaring Today

Insmed reported positive top-line results from a late-stage study of its antibiotic drug Arikayce. The data could improve the likelihood of success in more_horizontal

Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Insmed Incorporated (INSM) Q2 2023 Earnings Call Transcript

Insmed Incorporated (NASDAQ:INSM ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bryan Dunn - Head, IR William Lewis more_horizontal

Insmed Incorporated (INSM) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 6, 2023

Insmed Incorporated (INSM) Q1 2023 Earnings Call Transcript

Insmed Incorporated (NASDAQ:INSM ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Bryan Dunn - Head of Investor Relations more_horizontal

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 4, 2023

Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.08. This compares to loss of $0.80 more_horizontal


Search within

Pages Search Results: